Yahoo Finance

Truist lowered the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus’ April R&D day.

Don't Miss Our End of Quarter Offers:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on AUTL:

Disclaimer & DisclosureReport an Issue

• Autolus Therapeutics: Positive Momentum Amid Financial Challenges

• Autolus Therapeutics price target lowered to $6 from $8 at Wells Fargo

• Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects

• Autolus Therapeutics Reports Strong 2024 Results

• Optimistic Buy Rating for Autolus Therapeutics Driven by Strategic Advancements and Successful Launch of Aucatzyl